Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Jerini’s Icatibant Could Be Second To Market For Hereditary Angioedema

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Jerini submits NDA for bradykinin blocker just over two months after Lev Pharmaceuticals’ Cinryze was filed.

You may also be interested in...



Jerini’s Icatibant Falters in U.S., Wins In Europe

FDA rejects orphan drug for hereditary angioedema, paving way for rivals to gain an edge.

Jerini’s Icatibant Falters in U.S., Wins In Europe

FDA rejects orphan drug for hereditary angioedema, paving way for rivals to gain an edge.

Dyax/Bayer Schering Ink Antibody Discovery Agreement

External licensing and discovery agreements support internal pipeline growth, goal of total integration, Dyax CEO tells “The Pink Sheet” DAILY.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS065320

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By